Cardiovascular Imaging, Endocrine System Disease
Conditions
Keywords
Cushing's syndrome, cardiac steatosis, intramyocardial triglyceride content, 1H magnetic resonance spectroscopy and cardiac magnetic resonance imaging, Left Ventricularly hypertrophy
Brief summary
This study aims at evaluating the myocardial triglyceride content and cardiac structure and function, using 1H magnetic resonance spectroscopy and cardiac magnetic resonance imaging, in patients with Cushing's syndrome before and after treatment and in age-, sex- and BMI-matched healthy volunteers. The investigators make the hypothesis that Cushing's syndrome patients compared to healthy subjects present with excess lipid storage in cardiac myocytes, reversible upon correction of hypercortisolism.
Detailed description
Despite skeletal muscle atrophy, Cushing's syndrome patients have an increased Left Ventricular mass, reversible upon correction of the hypercortisolism. This may be due to cardiac steatosis, previously demonstrated in patients with diabetes mellitus. This study aims at evaluating the myocardial triglyceride content and cardiac structure and function, using 1H magnetic resonance spectroscopy and cardiac magnetic resonance imaging (CMRI), in patients with Cushing's syndrome and in age-, sex- and BMI-matched healthy volunteers. The patients will be stratified into two groups in function of the presence or absence of diabetes mellitus or impaired glucose and will be evaluated twice: before and 6 months after efficient treatment of Cushing's syndrome. We make the hypothesis that Cushing's syndrome patients compared to healthy subjects have excess lipid storage in cardiac myocytes irrespectively of the glucose homeostasis status, and that this lipid content will decrease after the correction of hypercortisolism.
Interventions
OTHER1H magnetic resonance spectroscopy and CMRI
Metabolic status of the patients evaluated by an OGTT (measuring plasma glucose, insulin and plasma nonesterified fatty acids concentrations) and myocardial Imaging and spectroscopy will be performed before and 6 month after treatment
Sponsors
Assistance Publique - Hôpitaux de Paris
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* group 1 and 2: patients with overt Cushing's syndrome, with 24-hour urinary free cortisol excretion over the two fold of the upper limit of the normal, with (group 1) or without (group 2) diabetes mellitus or glucose intolerance * group 3: healthy volunteers matched for age, sex and BMI with the patients of the group 2
Exclusion criteria
* contraindication of MRI * hypersensitivity to gadolinium * acute myocardial ischemia * renal insufficiency (creatinin clearance 30 mL/min/l,73m2) * pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Left Ventricular (LV) intramyocardial triglyceride / water ratio LV intramyocardial triglyceride / water ratio | Assessed twice in patients - before and 6 months after treatment - and once in volunteers | Intramyocardial triglyceride content will be assessed by 1H magnetic resonance spectroscopy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Left Ventricular intramyocardial fatt fraction (Dixon) | Assessed twice in patients - before and 6 months after treatment - and once in volunteers | In/Out of Phase Imaging (Dixon) |
| Subcutaneous and visceral abdominal fatt | Assessed twice in patients - before and 6 months after treatment - and once in volunteers | ISubcutaneous and visceral abdominal fat masses were determined from abdominal axial images at the L3 to L4 level |
| Cardiac morphology and function | Assessed twice in patients - before and 6 months after treatment - and once in volunteers | LV mass index, LA, LV and Right Ventricular (RV) ejection fractions and LV and RV stroke volumes assessed by Cardiac Magnetic Resonance Imaging (CMRI) |
Countries
France
Contacts
Primary ContactPhilippe CHANSON, MD, PhD
Backup ContactPeter KAMENICKY, MD
Outcome results
None listed